Table 4.
Continuous clinical outcomes for IL-6Ri and JAKi initiators: change from baseline to 6 months post-initiation
| Continuous outcomes | IL-6Ri Initiators (N = 100) | JAKi Initiators (N = 129) | IL-6Ri vs. JAKi Initiatorsb | |||
|---|---|---|---|---|---|---|
| Unadjusted change, mean (95% CI)a, n | Unadjusted β (95% CI) | p value | Adjusted β (95% CI)c | p value | ||
| CDAI | − 6.1 (− 9.2, − 3.0), 89 | − 2.6 (− 5.4, 0.3), 103 | − 0.34 (− 3.69, 3.00) | 0.84 | − 0.52 (− 4.09, 3.06) | 0.78 |
| HAQ | − 0.0 (− 0.1, 0.1), 85 | − 0.1 (− 0.2, − 0.0), 104 | 0.05 (− 0.08, 0.17) | 0.46 | 0.03 (− 0.11, 0.17) | 0.69 |
| Patient-reported pain | − 11.1 (− 16.9, − 5.4), 89 | − 6.4 (− 12.6, − 0.3), 106 | − 1.42 (− 8.59, 5.76) | 0.70 | − 1.21 (− 9.09, 6.68) | 0.76 |
| Patient-reported fatigue | − 6.1 (− 11.2, − 0.9), 89 | − 2.6 (− 8.0, 2.7), 103 | − 1.32 (− 7.85, 5.21) | 0.69 | − 2.52 (− 9.68, 4.64) | 0.49 |
| TJC | − 1.9 (− 3.4, − 0.3), 92 | − 1.4 (− 2.9, 0.1), 103 | − 0.00 (− 1.76, 1.75) | 1.00 | − 0.26 (− 2.20, 1.69) | 0.65 |
| SJC | − 1.9 (− 3.0, − 0.8), 92 | − 0.3 (− 1.3, 0.6), 103 | − 0.52 (− 1.69, 0.65) | 0.38 | − 0.28 (− 1.49, 0.93) | 0.65 |
| MDGA | − 13.8 (− 18.6, − 8.9), 92 | − 3.9 (− 8.5, 0.7), 104 | − 2.50 (− 8.09, 3.09) | 0.38 | − 1.90 (− 7.48, 3.69) | 0.50 |
| PtGA | − 9.0 (− 14.7, − 3.3), 89 | − 5.3 (− 11.4, 0.9), 106 | − 0.71 (− 7.88, 6.45) | 0.84 | − 0.72 (− 8.35, 6.90) | 0.85 |
| Morning stiffness durationd | − 1.3 (− 2.3, − 0.4), 89 | − 0.2 (− 1.3, 0.8), 104 | − 0.99 (− 1.98, − 0.00) | 0.05 | − 0.98 (− 1.99, 0.04) | 0.06 |
CDAI Clinical Disease Activity Index, CI confidence interval, HAQ Health Assessment Questionnaire, IL-6Ri interleukin-6 receptor inhibitor, JAKi Janus kinase inhibitor, MDGA Physician Global Assessment, n/N number of patients, PtGA Patient Global Assessment, SJC swollen joint count, TJC tender joint count
aCIs not inclusive of 0 represent statistically significant mean change from baseline within each group
bBaseline value of respective outcome included as covariate along with therapy group; OR are calculated using JAKi initiators as the reference group
cAdjusted β from multivariable linear regression models represent the estimated difference in the mean change in the outcome for IL-6Ri initiators compared with JAKi initiators, after adjusting for other covariates
dAmong those reporting morning stiffness at baseline